Actualités Acasti Pharma Inc - ACST | Actions TSX Venture Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference

LAVAL, Québec, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

LAVAL, Québec, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd

LAVAL, Québec, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma Announces Annual Stock Option Grants

LAVAL, Québec, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022

LAVAL, Québec, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call

LAVAL, Quebec, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST...

Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan

LAVAL, Québec, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

LAVAL, Québec, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”...

Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

LAVAL, Québec, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”...

Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ

LAVAL, Québec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”...

Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

LAVAL, Québec, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”...

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti”) (NASDAQ: ACST–TSX-V:...

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022

August 4th webcast replay discussing planned acquisition of Grace Therapeutics available on the Company’s...

Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

LAVAL, Québec, July 29, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

LAVAL, Québec, July 23, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq:...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Acasti Pharma Inc (ACST)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

ACST Actualités

Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference

Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd

Acasti Pharma Announces Annual Stock Option Grants

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022

Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call

Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ

Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022

Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Acasti Pharma Inc (ACST) Actualités

Acasti Pharma Inc (ACST)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

ACST Actualités

Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 Conference

Acasti Pharma Announces Interim Data Meets All Primary Endpoints for Pivotal PK Study for GTX-104

Acasti Pharma CEO to Participate in the Benzinga All Access Event on December 2nd

Acasti Pharma Announces Annual Stock Option Grants

Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2022

Acasti Pharma Schedules Second Quarter Fiscal 2022 Business Update Conference Call

Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ

Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022

Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

BLACK FRIDAY

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres